Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen-Reference-Cited by-同舟云学术

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen

Published:2021-05 Issue:8 Volume:15 Page:2026-2045
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Barkovskaya Anna¹²^ORCID,Goodwin Craig M.³,Seip Kotryna¹,Hilmarsdottir Bylgja¹⁴⁵,Pettersen Solveig¹,Stalnecker Clint³,Engebraaten Olav¹⁶⁷,Briem Eirikur⁴⁸,Der Channing J.³,Moestue Siver A.²⁹^ORCID,Gudjonsson Thorarinn⁴¹⁰,Mælandsmo Gunhild M.¹¹¹^ORCID,Prasmickaite Lina¹^ORCID

Affiliation:

1. Department of Tumor Biology Institute for Cancer Research Oslo University Hospital The Norwegian Radium Hospital Oslo Norway

2. Department of Circulation and Medical Imaging Norwegian University of Science and Technology Trondheim Norway

3. Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill NC USA

4. Biomedical Center School of Health Sciences University of Iceland Reykjavik Iceland

5. Department of Pathology Landspitali University Hospital Reykjavik Iceland

6. Institute of Clinical Medicine Faculty of Medicine University of Oslo Norway

7. Department of Oncology Oslo University Hospital Norway

8. Department of Genetics and Molecular Medicine Landspitali University Hospital Reykjavik Iceland

9. Department of Health Sciences Nord University Bodø Norway

10. Department of Laboratory Hematology Landspitali University Hospital Reykjavik Iceland

11. Faculty of Health Sciences Institute of Medical Biology The Arctic University of Norway – University of Tromsø Norway

Funder

Kreftforeningen

NIH Clinical Center

Norges Forskningsråd

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12951

Reference65 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance

3. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

4. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression

5. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research;Cancers;2023-09-01

2. Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement;Materials Today Bio;2022-12

3. UDP‐glucose dehydrogenase expression is upregulated following EMT and differentially affects intracellular glycerophosphocholine and acetylaspartate levels in breast mesenchymal cell lines;Molecular Oncology;2022-02-03